Cleveland BioLabs, Inc. (CBLI) Receives an Increase in DoD Protectan CBLB502 Contract
Up)
Cleveland BioLabs, Inc. (Nasdaq: CBLI) announced today that the Chemical Biological Medical Systems Medical Identification and Treatment Systems Joint Program Executive Office (CBMS-MITS JPEO) of The Department of Defense (DoD) incresed the ongoing contract for the developmental studies related to Protectan CBLB502. The contract, awarded in April 2008, will increase from $8.86 million to $9.59 million.
You May Also Be Interested In
- DISH Network (DISH) Sued by Networks for 'Commercial Skipping' Feature
- Socket Mobile (SCKT) Receives Non-Compliance Notification From NASDAQ
- Heritage Oaks Bancorp (HEOP) pays deferred interest on TARP preferreds
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
